Logic of Selecting Suitable Dissolution Parameters in New Drug Formulations Based on A BCS Approach

Area of Science:

• Pharmaceutical Sciences
• Drug Product Quality Assessment
• Biopharmaceutical Classification System (BCS)

Background:

• Generic drug quality relies on reference product standards.
• Limited literature exists on in vitro drug release under varied conditions.
• Understanding in vitro release is crucial for biopharmaceutical quality.

Purpose of the Study:

• Evaluate the in vitro release performance of four reference drug tablets.
• Compare dissolution profiles across different agitation rates and apparatus types.
• Assess the impact of drug dose on in vitro release characteristics.

Main Methods:

• Dissolution testing of propranolol-HCl, carbamazepine, ranitidine-HCl, and metronidazole.
• Utilized USP basket and paddle apparatus at 50, 75, and 100 rpm.
• Employed pharmacopeial dissolution media and automated sampling; analyzed data using model-independent, model-dependent, and ANOVA methods.

Main Results:

• Significant differences (P < 0.05) observed between low and high drug doses.
• Basket and paddle apparatus produced comparable in vitro results under certain conditions.
• Hydrodynamic environment variations did not consistently alter drug release patterns.

Conclusions:

• Drug dose significantly influences in vitro release, potentially affecting biowaiver requests for propranolol-HCl and ranitidine-HCl.
• Dissolution test design must consider dose, agitation rate, and apparatus type.
• Comparable in vitro data can be achieved with different apparatus under specific settings, aiding in developing dissolution tests for new dosages.